间日疟的临床影响:一项合集综述
本合集综述纳入快速系统综述与随机效应Meta分析,估计全部门诊及住院间日疟患者中WHO定义重症比例为0.7%与7.11%,死亡率为0.01%与0.56%;幼儿和孕妇是脆弱人群。
要点
- 全部门诊间日疟患者中WHO定义重症比例为0.7%(95%CI 0.19%至2.57%)。
- 住院间日疟患者中WHO定义重症比例为7.11%(95%CI 4.30%至11.55%)。
- 幼儿和孕妇是间日疟不良临床影响的主要脆弱人群。
核心结论
- 幼儿和孕妇尤其易受间日疟不良临床影响,预防该人群感染和复发是优先事项。
- 过去10年积累了间日疟重症表现的大量证据,但报告不一致。
- 存在重大知识空白,例如对潜在病理生理及报告并发症地理分布异质性原因的了解有限。
- 改编的间日疟重症病例定义将有助于监测和未来研究以更好地理解该病。
研究设计与样本
- 合集综述,包含对重症疾病的快速系统综述,并对分母定义明确的研究数据进行Meta分析,按住院状态分层。
- 检索423篇文章,其中311篇(74%)发表于2010年以来。
- 随机效应Meta分析纳入85项研究,其中68项为住院间日疟患者研究。
主要发现
- 自1929年以来报告超过11,658例重症间日疟患者,共15,954次重症疟疾表现,其中仅7,157次(45%)符合WHO诊断标准。
- 全部门诊间日疟患者中WHO定义重症比例为0.7%(95%CI 0.19%至2.57%),住院患者为7.11%(95%CI 4.30%至11.55%)。
- 全部患者中间日疟死亡率为0.01%(95%CI 0.00%至0.07%),住院环境中为0.56%(95%CI 0.35%至0.92%)。
- WHO定义脑型、呼吸和肾脏重症并发症在所有纳入研究中一般估计发生于不足0.5%的患者。
- 流行区儿童复发感染可致严重贫血,间日疟导致发病率和死亡率增加及学业表现受损;妊娠期感染与母亲贫血、早产、胎儿丢失和低出生体重相关。
关键数值与推荐
- WHO定义重症间日疟在全部患者中比例为0.7%(95%CI 0.19%至2.57%)。
- WHO定义重症间日疟在住院患者中比例为7.11%(95%CI 4.30%至11.55%)。
- 间日疟死亡率在全部患者中为0.01%(95%CI 0.00%至0.07%),住院环境中为0.56%(95%CI 0.35%至0.92%)。
- WHO定义脑型、呼吸和肾脏重症并发症一般估计发生于不足0.5%的患者。
临床怎么用
- 作者认为预防幼儿和孕妇间日疟感染和复发是优先事项。
- 作者认为改编的间日疟重症病例定义将有助于监测和未来研究。
局限性
- 本综述局限性包括大多数重症间日疟研究为观察性且规模小。
- 纳入研究异质性高,且研究主要在住院患者中进行(因此更可能病情严重)。
- 偏倚风险高,包括小研究效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasmodium vivax infects an estimated 7 million people every year. Previously, vivax malaria was perceived as a benign condition, particularly when compared to falciparum malaria. Reports of the severe clinical impacts of vivax malaria have been increasing over the last decade. METHODS AND FINDINGS: We describe the main clinical impacts of vivax malaria, incorporating a rapid systematic review of severe disease with meta-analysis of data from studies with clearly defined denominators, stratified by hospitalization status. Severe anemia is a serious consequence of relapsing infections in children in endemic areas, in whom vivax malaria causes increased morbidity and mortality and impaired school performance. P. vivax infection in pregnancy is associated with maternal anemia, prematurity, fetal loss, and low birth weight. More than 11,658 patients with severe vivax malaria have been reported since 1929, with 15,954 manifestations of severe malaria, of which only 7,157 (45%) conformed to the World Health Organization (WHO) diagnostic criteria. Out of 423 articles, 311 (74%) were published since 2010. In a random-effects meta-analysis of 85 studies, 68 of which were in hospitalized patients with vivax malaria, we estimated the proportion of patients with WHO-defined severe disease as 0.7% [95% confidence interval (CI) 0.19% to 2.57%] in all patients with vivax malaria and 7.11% [95% CI 4.30% to 11.55%] in hospitalized patients. We estimated the mortality from vivax malaria as 0.01% [95% CI 0.00% to 0.07%] in all patients and 0.56% [95% CI 0.35% to 0.92%] in hospital settings. WHO-defined cerebral, respiratory, and renal severe complications were generally estimated to occur in fewer than 0.5% patients in all included studies. Limitations of this review include the observational nature and small size of most of the studies of severe vivax malaria, high heterogeneity of included studies which were predominantly in hospitalized patients (who were therefore more likely to be severely unwell), and high risk of bias including small study effects. CONCLUSIONS: Young children and pregnant women are particularly vulnerable to adverse clinical impacts of vivax malaria, and preventing infections and relapse in this groups is a priority. Substantial evidence of severe presentations of vivax malaria has accrued over the last 10 years, but reporting is inconsistent. There are major knowledge gaps, for example, limited understanding of the underlying pathophysiology and the reason for the heterogenous geographical distribution of reported complications. An adapted case definition of severe vivax malaria would facilitate surveillance and future research to better understand this condition.
引用
- Phyo AP, Dahal P, Mayxay M, et al. Clinical impact of vivax malaria: A collection review. PLoS Med. 2022. PMID: 35041650. doi:10.1371/journal.pmed.1003890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。